The strong predictive performance of our glycemic biomarkers, together with the biological plausibility, suggests that hyperglycemia may, in some infants, act as a driver of VEGF dysregulation or, alternatively, may amplify disease progression in the presence of other concurrent risk factors. The gene discussed is VEGFA; the disease is Hyperglycemia.